Competing risks of death and kidney failure in a cohort of Australian adults with severe chronic kidney disease.


Journal

The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714

Informations de publication

Date de publication:
21 Feb 2022
Historique:
revised: 09 07 2021
received: 08 01 2021
accepted: 21 07 2021
pubmed: 7 12 2021
medline: 5 3 2022
entrez: 6 12 2021
Statut: ppublish

Résumé

To examine the competing risks of death (any cause) and of kidney failure in a cohort of Australian adults with severe chronic kidney disease. Population-based cohort study; analysis of linked data from the Tasmanian Chronic Kidney Disease study (CKD.TASlink), 1 January 2004 - 31 December 2017. All adults in Tasmania with incident stage 4 chronic kidney disease (estimated glomerular filtration rate [eGFR], 15-29 mL/min/1.73 m Death or kidney failure (defined as eGFR below 10 mL/min/1.73 m We included data for 6825 adults with incident stage 4 chronic kidney disease (mean age, 79.3 years; SD, 11.1 years), including 3816 women (55.9%). The risk of death increased with age - under 65 years: 0.18 (95% CI, 0.15-0.22); 65-74 years: 0.39 (95% CI, 0.36-0.42); 75-84 years, 0.56 (95% CI, 0.54-0.58); 85 years or older: 0.78 (95% CI, 0.77-0.80) - while that of kidney failure declined - under 65 years: 0.39 (95% CI, 0.35-0.43); 65-74 years: 0.12 (95% CI, 0.10-0.14); 75-84 years: 0.05 (95% CI, 0.04-0.06); 85 years or older: 0.01 (95% CI, 0.01-0.02). The risk of kidney failure was greater for people with macroalbuminuria and those whose albumin status had not recently been assessed. The risks of kidney failure and death were greater for men than women in all age groups (except similar risks of death for men and women under 65 years of age). For older Australians with incident stage 4 chronic kidney disease, the risk of death is higher than that of kidney failure, and the latter risk declines with age. Clinical guidelines should recognise these competing risks and include recommendations about holistic supportive care, not just on preparation for dialysis or transplantation.

Identifiants

pubmed: 34866191
doi: 10.5694/mja2.51361
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

140-146

Subventions

Organisme : Tasmanian Community Fund
Organisme : Royal Hobart Hospital Research Foundation
ID : 20-201

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 AMPCo Pty Ltd.

Références

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl 2013; 3: 1-150.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
Australian Institute of Health and Welfare. Deaths in Australia (Cat. no. PHE 229). Updated 7 Aug 2020. https://www.aihw.gov.au/reports/life-expectancy-death/deaths-in-australia (viewed Sept 2020).
Austin PC, Fine JP. Accounting for competing risks in randomized controlled trials: a review and recommendations for improvement. Stat Med 2017; 36: 1203-1209.
Ravani P, Quinn R, Fiocco M, et al. Association of age with risk of kidney failure in adults with stage IV chronic kidney disease in Canada. JAMA Netw Open 2020; 3: e2017150.
Saunder T, Kitsos A, Radford J, et al. Chronic kidney disease in Tasmania: protocol for a data linkage study. JMIR Res Protoc 2020; 9: e20160.
Australian Bureau of Statistics. ERP by SA2 (ASGS 2016), age and sex, 2001 onwards [dataset: reference period: 30 June 2001 - 30 June 2019. https://stat.data.abs.gov.au/Index.aspx?DataSetCode=ABS_ERP_ASGS2016 (viewed June 2021).
Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
Jose MD, Otahal P, Kirkland G, et al. Retrospective standardisation of serum creatinine identified changes in eGFR over time [abstract: Australian and New Zealand Society of Nephrology, 44th annual scientific meeting, Newcastle, Australia, 6-10 Sept 2008]. Nephrology 2008; 13 (Suppl 3): A101.
Royal Australasian College of Pathologists. Albumin urine (RCPA manual). https://www.rcpa.edu.au/Manuals/RCPA-Manual/Pathology-Tests/A/Albumin-urine (viewed Oct 2021).
Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
Goldman N, Glei DA, Weinstein M. The best predictors of survival: do they vary by age, sex, and race? Popul Dev Rev 2017; 43: 541-560.
House JS, Lepkowski JM, Kinney AM, et al. The social stratification of aging and health. J Health Soc Behav 1994; 35: 213-234.
O’Hare AM. How useful is an age-neutral model of chronic kidney disease? JAMA Netw Open 2020; 3: e2017592.
Murtagh FE, Burns A, Moranne O, et al. Supportive care: comprehensive conservative care in end-stage kidney disease. Clin J Am Soc Nephrol 2016; 11: 1909-1914.
Raj R, Brown B, Ahuja K, et al. Enabling good outcomes in older adults on dialysis: a qualitative study. BMC Nephrol 2020; 21: 28.
Piccoli GB, Alrukhaimi M, Liu ZH, et al; World Kidney Day Steering Committee. Women and kidney disease: reflections on World Kidney Day 2018. Kidney Int 2018; 93: 278-283.

Auteurs

Matthew D Jose (MD)

University of Tasmania, Hobart, TAS.
Royal Hobart Hospital, Hobart, TAS.

Rajesh Raj (R)

Launceston General Hospital, Launceston, TAS.
University of Tasmania, Launceston, TAS.

Kim Jose (K)

Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS.

Alex Kitsos (A)

University of Tasmania, Hobart, TAS.

Tim Saunder (T)

University of Tasmania, Hobart, TAS.

Charlotte McKercher (C)

Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS.

Jan Radford (J)

Launceston General Hospital, Launceston, TAS.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH